MetaVia (MTVA) Competitors

$3.94 +1.07 (+37.11%)

As of 02:54 PM Eastern

MTVA vs. ALVR, AYTU, MRKR, OTLK, and ALLR

Should you buy MetaVia stock or one of its competitors? MarketBeat compares MetaVia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MetaVia include AlloVir (ALVR), Aytu BioPharma (AYTU), Marker Therapeutics (MRKR), Oncobiologics (OTLK), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry.

How does MetaVia compare to AlloVir?

AlloVir (NASDAQ:ALVR) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

AlloVir's return on equity of -71.03% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
MetaVia	N/A	-172.92%	-89.39%

MetaVia has a consensus price target of $20.00, suggesting a potential upside of 404.54%. Given MetaVia's stronger consensus rating and higher probable upside, analysts clearly believe MetaVia is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

In the previous week, MetaVia had 17 more articles in the media than AlloVir. MarketBeat recorded 17 mentions for MetaVia and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 beat MetaVia's score of -0.29 indicating that AlloVir is being referred to more favorably in the media.

Company	Overall Sentiment
AlloVir	Neutral
MetaVia	Neutral

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 0.8% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Summary

AlloVir beats MetaVia on 7 of the 13 factors compared between the two stocks.

How does MetaVia compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Aytu BioPharma has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

MetaVia has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
MetaVia	N/A	-172.92%	-89.39%

MetaVia has lower revenue, but higher earnings than Aytu BioPharma. MetaVia is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

In the previous week, MetaVia had 15 more articles in the media than Aytu BioPharma. MarketBeat recorded 17 mentions for MetaVia and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.17 beat MetaVia's score of -0.29 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aytu BioPharma presently has a consensus target price of $9.33, suggesting a potential upside of 325.21%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 404.54%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 0.8% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Aytu BioPharma beats MetaVia on 10 of the 15 factors compared between the two stocks.

How does MetaVia compare to Marker Therapeutics?

MetaVia (NASDAQ:MTVA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, MetaVia and MetaVia both had 17 articles in the media. Marker Therapeutics' average media sentiment score of 0.52 beat MetaVia's score of -0.29 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics has higher revenue and earnings than MetaVia. Marker Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Marker Therapeutics	$3.55M	6.67	-$12.16M	-$0.61	N/A

MetaVia has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 404.54%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 604.23%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

MetaVia has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

1.4% of MetaVia shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 0.8% of MetaVia shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Marker Therapeutics beats MetaVia on 12 of the 14 factors compared between the two stocks.

How does MetaVia compare to Oncobiologics?

MetaVia (NASDAQ:MTVA) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

MetaVia currently has a consensus target price of $20.00, indicating a potential upside of 404.54%. Oncobiologics has a consensus target price of $4.50, indicating a potential upside of 1,297.52%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oncobiologics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Oncobiologics	N/A	N/A	-291.28%

1.4% of MetaVia shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 0.8% of MetaVia shares are held by insiders. Comparatively, 2.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MetaVia has higher earnings, but lower revenue than Oncobiologics. MetaVia is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Oncobiologics	$1.35M	28.83	-$62.42M	-$1.17	N/A

In the previous week, MetaVia had 14 more articles in the media than Oncobiologics. MarketBeat recorded 17 mentions for MetaVia and 3 mentions for Oncobiologics. MetaVia's average media sentiment score of -0.29 beat Oncobiologics' score of -1.00 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

MetaVia has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Oncobiologics beats MetaVia on 7 of the 12 factors compared between the two stocks.

How does MetaVia compare to Allarity Therapeutics?

MetaVia (NASDAQ:MTVA) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

In the previous week, MetaVia had 14 more articles in the media than Allarity Therapeutics. MarketBeat recorded 17 mentions for MetaVia and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.00 beat MetaVia's score of -0.29 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics has higher revenue and earnings than MetaVia. Allarity Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Allarity Therapeutics	$345K	78.86	-$11.23M	-$0.72	N/A

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 404.54%. Allarity Therapeutics has a consensus price target of $9.75, indicating a potential upside of 470.18%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Allarity Therapeutics' return on equity of -109.94% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Allarity Therapeutics	N/A	-109.94%	-47.27%

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Allarity Therapeutics beats MetaVia on 8 of the 12 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.05M	$3.38B	$6.39B	$12.33B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-0.75	19.03	21.06	25.70
Price / Sales	N/A	299.85	580.13	99.36
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	2.25	6.98	10.10	7.04
Net Income	-$12.97M	$24.45M	$3.55B	$335.04M
7 Day Performance	257.12%	3.76%	4.91%	2.69%
1 Month Performance	146.21%	-0.17%	1.57%	1.49%
1 Year Performance	-55.51%	62.88%	36.63%	35.72%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	1.9685 of 5 stars	$3.94 +37.1%	$20.00 +408.3%	-70.2%	$20.32M	N/A	N/A	8	News Coverage Analyst Revision Gap Up High Trading Volume
ALVR AlloVir	N/A	$4.83 +0.8%	N/A	+45.0%	$24.36M	N/A	N/A	110	High Trading Volume
AYTU Aytu BioPharma	2.3103 of 5 stars	$2.25 flat	$9.33 +314.8%	+5.4%	$24.15M	$62.64M	N/A	160	Gap Up
MRKR Marker Therapeutics	3.0755 of 5 stars	$1.45 +1.4%	$10.00 +589.7%	+30.0%	$24.08M	N/A	N/A	60	Earnings Report Analyst Forecast Analyst Revision
OTLK Oncobiologics	2.1246 of 5 stars	$0.23 -2.2%	$4.50 +1,900.0%	-79.6%	$23.54M	$1.35M	N/A	20	Negative News Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors

MTVA vs. ALVR, AYTU, MRKR, OTLK, and ALLR

How does MetaVia compare to AlloVir?

Summary

How does MetaVia compare to Aytu BioPharma?

Summary

How does MetaVia compare to Marker Therapeutics?

Summary

How does MetaVia compare to Oncobiologics?

Summary

How does MetaVia compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetaVia (MTVA) Competitors

MTVA vs. ALVR, AYTU, MRKR, OTLK, and ALLR

How does MetaVia compare to AlloVir?

Is ALVR or MTVA more profitable?

Do analysts recommend ALVR or MTVA?

Which has better earnings & valuation, ALVR or MTVA?

Does the media prefer ALVR or MTVA?

Do insiders & institutionals hold more shares of ALVR or MTVA?

Which has more volatility and risk, ALVR or MTVA?

Summary

How does MetaVia compare to Aytu BioPharma?

Which has more risk & volatility, AYTU or MTVA?

Is AYTU or MTVA more profitable?

Which has higher earnings and valuation, AYTU or MTVA?

Does the media favor AYTU or MTVA?

Do analysts recommend AYTU or MTVA?

Do institutionals and insiders hold more shares of AYTU or MTVA?

Summary

How does MetaVia compare to Marker Therapeutics?

Does the media refer more to MTVA or MRKR?

Which has higher valuation and earnings, MTVA or MRKR?

Is MTVA or MRKR more profitable?

Do analysts rate MTVA or MRKR?

Which has more risk and volatility, MTVA or MRKR?

Do insiders and institutionals hold more shares of MTVA or MRKR?

Summary

How does MetaVia compare to Oncobiologics?

Do analysts rate MTVA or OTLK?

Is MTVA or OTLK more profitable?

Do institutionals & insiders hold more shares of MTVA or OTLK?

Which has stronger earnings & valuation, MTVA or OTLK?

Does the media refer more to MTVA or OTLK?

Which has more risk & volatility, MTVA or OTLK?

Summary

How does MetaVia compare to Allarity Therapeutics?

Does the media refer more to MTVA or ALLR?

Which has preferable valuation & earnings, MTVA or ALLR?

Do analysts prefer MTVA or ALLR?

Which has more volatility and risk, MTVA or ALLR?

Is MTVA or ALLR more profitable?

Do insiders & institutionals have more ownership in MTVA or ALLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools